ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications
ASCArdmore Shipping(ASC) GlobeNewswire News Room·2024-10-07 19:55

New Scientific Advisory Board (SAB) comprised of five leading experts in the areas of obesity and metabolic diseases, and four leading inflammasome experts and inventors of IC 100 from University of Miami Miller School of Medicine who have provided ongoing scientific advisory support for IC 100 since its license. WESTON, Fla., Oct. 07, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for tre ...